Oxford Events, the new replacement for OxTalks, will launch on 16th March. From now until the launch of Oxford Events, new events cannot be published or edited on OxTalks while all existing records are migrated to the new platform. The existing OxTalks site will remain available to view during this period.
From 16th, Oxford Events will launch on a new website: events.ox.ac.uk, and event submissions will resume. You will need a Halo login to submit events. Full details are available on the Staff Gateway.
Marcus Flather graduated from the Royal Free Hospital School of Medicine and trained in general medicine and cardiology in London and Oxford. In 1988 he joined CTSU at the University of Oxford, working on large clinical trials in acute coronary syndromes, and continued this work at McMaster University from 1993-1996 before being appointed Director of the Clinical Trials and Evaluation Unit and Consultant Cardiologist at Royal Brompton and Harefield Hospitals.
In September 2011 he was appointed Professor of Medicine and Clinical Trials at the University of East Anglia and Director of Research at the Norfolk and Norwich University Hospitals NHS Foundation Trust in Norwich. He is a recognised expert in clinical trials and has more than 20 years’ experience collaborating with academic and industry partners in drug and device development.
In this seminar, Professor Flather will discuss results from the recently published CANTOS trial in which canakinumab therapy yielded benefit for both cardiovascular and cancer outcomes.
